Genentech/Roche's Avastin fails Phase III study in early-stage colon cancer
22 April 2009
Katie McQue
Genentech/
Roche's anti-angiogenic monoclonal antibody Avastin (bevacizumab) has failed to meet the primary endpoint of disease-free survival in its Phase III trial of use as adjuvant therapy in early-stage colon cancer.
"Avastin's first key adjuvant data is negative, calling into serious question...
Please Login to read the full article.
22 April 2009
Katie McQue
"Avastin's first key adjuvant data is negative, calling into serious question...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Hope not enough for Avastin in MBC; Hamburg explains withdrawal
- Merck decision to bail from TLR9 agonist programme upsets Idera investors
- NICE rejects Merck Serono's Erbitux, Roche's Avastin and Amgen's Vectibix for second line mCRC
- NICE says no to three colorectal cancer drugs
ANALYSIS
Other Informa Analysis
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
